Sci PharmtechTPE:4119 -0.34%67 ROA % is 2.26% as of Dec. 2025, which is 69% below its 10-year median of 7.23. GuruFocus rates TPE:4119 with a GF Score™ of 67/100 and a GF Value™ of NT$96.43 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Sci Pharmtech ranks worse than 56.53% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sci Pharmtech's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$155 Mil.
Sci Pharmtech's average Total Assets over the quarter that ended in Dec. 2025 was NT$6,870 Mil. Therefore, Sci Pharmtech's annualized ROA % for the quarter that ended in Dec. 2025 was 2.26%.
The historical rank and industry rank for Sci Pharmtech's ROA % or its related term are showing as below:
TPE:4119'
s ROA % Range Over the Past 10 Years
Min: 1.27 Med: 7.23 Max: 14.51
Current: 1.53
During the past 13 years, Sci Pharmtech's highest ROA % was 14.51%. The lowest was 1.27%. And the median was 7.23%.
TPE:4119's ROA % is ranked worse than 56.53% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.69
vs TPE:4119: 1.53
Sci Pharmtech (TPE:4119) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Sci Pharmtech ROA % Related Terms
Sci Pharmtech ROA % Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's ROA % distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Sci Pharmtech (TPE:4119) has a ROA % of 2.26% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sci Pharmtech and its competitors. This is 69% below median its historical median of 7.23. Over the past decade, Sci Pharmtech's ROA % has ranged from 1.27 to 14.51. According to the industry distribution chart, Sci Pharmtech ranks #567 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 56.5%.
Is Sci Pharmtech's ROA % too high?
Sci Pharmtech's current ROA % of 2.26% is 69% below median its 10-year median of 7.23. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 14.51. The Drug Manufacturers industry median ROA % is 2.69. Sci Pharmtech's value of 2.26% is 16% below this industry median. Based on the distribution chart, Sci Pharmtech ranks #567 out of 1003 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sci Pharmtech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #567 out of 1003 companies for ROA %. This places Sci Pharmtech in the lower half of its industry. The industry median ROA % is 2.69. Sci Pharmtech's value of 2.26% is 16% below this benchmark. Historically, Sci Pharmtech's own ROA % has ranged from 1.27 to 14.51 over the past decade. While the company's 10-year median is 7.23 vs. the industry median of 2.69, Sci Pharmtech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current ROA % of 2.26% is 16% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current ROA % is 2.26%, which is 69% below median its own 10-year median of 7.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$96.43, compared to a current price of NT$44.50 — trading 53.9% below its estimated fair value. The current ROA % is 2.26%, which is 69% below median its 10-year median of 7.23 and 16% below the Drug Manufacturers industry median of 2.69. Sci Pharmtech's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current ROA % is 2.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$44.50 is trading 53.9% below its estimated GF Value™ of NT$96.43.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
ROA %: 2.26% (69% below median its 10-year median of 7.23)
GF Value™: NT$96.43 vs. price of NT$44.50 (53.9% below fair value)
Industry Position: 16% below the Drug Manufacturers median (#567 of 1003)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
67GF Score
Get the complete analysis for TPE:4119
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
